Drug Res (Stuttg) 2016; 66(04): 169-173
DOI: 10.1055/s-0035-1565083
© Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetics of Alternative Administration Routes of Melatonin: A Systematic Review

D. Zetner
1   Department of Surgery, Center for Perioperative Optimization, Herlev Hospital, University of Copenhagen, Herlev, Denmark
L. P. H. Andersen
1   Department of Surgery, Center for Perioperative Optimization, Herlev Hospital, University of Copenhagen, Herlev, Denmark
J. Rosenberg
1   Department of Surgery, Center for Perioperative Optimization, Herlev Hospital, University of Copenhagen, Herlev, Denmark
› Author Affiliations
Further Information

Publication History

received 15 September 2015

accepted 06 October 2015

Publication Date:
29 October 2015 (online)


Background: Melatonin is traditionally administered orally but has a poor and variable bioavailability. This study aims to present an overview of studies investigating the pharmacokinetics of alternative administration routes of melatonin.

Methods: A systematic literature search was performed and included experimental or clinical studies, investigating pharmacokinetics of alternative administration routes of melatonin in vivo. Alternative administration routes were defined as all administration routes except oral and intravenous.

Results: 10 studies were included in the review. Intranasal administration exhibited a quick absorption rate and high bioavailability. Transdermal administration displayed a variable absorption rate and possible deposition of melatonin in the skin. Oral transmucosal administration of melatonin exhibited a high plasma concentration compared to oral administration. Subcutaneous injection of melatonin displayed a rapid absorption rate compared to oral administration.

Conclusion: Intranasal administration of melatonin has a large potential, and more research in humans is warranted. Transdermal application of melatonin has a possible use in a local application, due to slow absorption and deposition in the skin. Oral transmucosal administration may potentially be a clinically relevant due to avoiding first-pass metabolism. Subcutaneous injection of melatonin did not document any advantages compared to other administration routes.

  • References

  • 1 Nir I. Melatonin for the treatment of disorders in circadian rhythm and sleep: could it form a basis for medication?. Receptors Channels 2003; 9: 379-385
  • 2 Garfinkel D, Laudon M, Nof D et al. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995; 346: 541-544
  • 3 Petrie K, Dawson AG, Thompson L et al. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. Biol Psychiatry 1993; 33: 526-530
  • 4 Borazan H, Tuncer S, Yalcin N et al. Effects of preoperative oral melatonin medication on postoperative analgesia, sleep quality, and sedation in patients undergoing elective prostatectomy: a randomized clinical trial. J Anesth 2010; 24: 155-160
  • 5 Caumo W, Torres F, Moreira Jr NL et al. The clinical impact of preoperative melatonin on postoperative outcomes in patients undergoing abdominal hysterectomy. Anesth Analg 2007; 105: 1263-1271 table of contents
  • 6 Gitto E, Romeo C, Reiter RJ et al. Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg 2004; 39: 184-189 discussion-9
  • 7 Kucukakin B, Lykkesfeldt J, Nielsen HJ et al. Utility of melatonin to treat surgical stress after major vascular surgery – a safety study. J Pineal Res 2008; 44: 426-431
  • 8 DeMuro RL, Nafziger AN, Blask DE et al. The absolute bioavailability of oral melatonin. J Clin Pharmacol 2000; 40: 781-784
  • 9 Lane EA, Moss HB. Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab 1985; 61: 1214-1216
  • 10 Di WL, Kadva A, Johnston A et al. Variable bioavailability of oral melatonin. N Engl J Med 1997; 336: 1028-1029
  • 11 Harpsoe NG, Andersen LP, Gogenur I et al. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol 2015; 71: 901-909
  • 12 Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-341
  • 13 Moher D, Shamseer L, Clarke M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1
  • 14 van den Berg MP, Merkus P, Romeijn SG et al. Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparison with a human study. Pharm Res 2004; 21: 799-802
  • 15 Merkus P, Guchelaar HJ, Bosch DA et al. Direct access of drugs to the human brain after intranasal drug administration?. Neurology 2003; 60: 1669-1671
  • 16 Bechgaard E, Lindhardt K, Martinsen L. Intranasal absorption of melatonin in vivo bioavailability study. Int J Pharm 1999; 182: 1-5
  • 17 Mao S, Chen J, Wei Z et al. Intranasal administration of melatonin starch microspheres. Int J Pharm 2004; 272: 37-43
  • 18 Aeschbach D, Lockyer BJ, Dijk DJ et al. Use of transdermal melatonin delivery to improve sleep maintenance during daytime. Clin Pharmacol Ther 2009; 86: 378-382
  • 19 Priano L, Esposti D, Esposti R et al. Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J Nanosci Nanotechnol 2007; 7: 3596-3601
  • 20 Benes L, Claustrat B, Horriere F et al. Transmucosal, oral controlled-release, and transdermal drug administration in human subjects: a crossover study with melatonin. J Pharm Sci 1997; 86: 1115-1119
  • 21 Bangha E, Lauth D, Kistler GS et al. Daytime serum levels of melatonin after topical application onto the human skin. Skin Pharmacol 1997; 10: 298-302
  • 22 Bartoli AN, De Gregori S, Molinaro M et al. Bioavailability of a new oral spray melatonin emulsion compared with a standard oral formulation in healthy volunteers. Journal of Bioequivalence and Bioavailability 2012; 4: 96-99
  • 23 Kennaway DJ, Seamark RF. Circulating levels of melatonin following its oral administration or subcutaneous injection in sheep and goats. Aust J Biol Sci 1980; 33: 349-353
  • 24 Fourtillan JB, Brisson AM, Gobin P et al. Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. Biopharm Drug Dispos 2000; 21: 15-22
  • 25 Scheuer C, Pommergaard HC, Rosenberg J et al. Melatonin’s protective effect against UV radiation: a systematic review of clinical and experimental studies. Photodermatol Photoimmunol Photomed 2014; 30: 180-188